ArticleTranslational cancer research2021
Decreased expression of nuclear factor 90 correlates with worse outcomes in nasopharyngeal carcinoma.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNuclear factor 90 (NF90), one of the double-stranded RNA binding proteins (DSRBP), is involved in many cellular biological processes, includes cell proliferation, differentiation, angiogenesis, cell cycle and immunity. However, its role in nasopharyngeal carcinoma (NPC), and the significance of expression in clinics, remains unknown. The aim of this study was to uncover the relationship between the NF90 expression by immunohistochemistry (IHC) and clinical outcomes in NPC patients.
methodsWe retrospectively detected the NF90 expression in 216 NPC specimens by IHC. The cutoff value of NF90 was evaluated using receiver operating characteristic (ROC) curve, the prognostic value of NF90 in NPC was evaluated by Kaplan-Meier and cox multifactor statistical model.
resultsElevated expression of NF90 was found in 60.2% (130/216). Positive correlation was found between NF90 expression and clinical stage (P=0.018), T stage (P=0.004), and therapy (P=0.020). Over-expression of NF90 predicted favorable progression-free survival (PFS) (P=0.017) and overall survival (OS) (P<0.001) in NPC. Further analysis suggested that the level of NF90 expression was an independent risk factor in NPC prognosis.
conclusionsThese results demonstrate, for the first time, that decreased expression of NF90 is an independent biomarker of worse prognosis for NPC patients, and is a great potential tool for screening the high-risk population for advanced NPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.